November 1 - 3 BioMalaysia 2010 Conference & Exhibition Kuala Lumpur Convention Centre, Malaysia
This was the premier biotechnology event of the year for BiotechCorp to showcase latest research findings, state-of-the-art technology and new product launches. It also served as a platform for experts to engage in an exchange of knowledge, experiences and opinions in the development of the biotechnology industries. The event attracted over 7,400 participants from 17 countries.
November 13 - 14 BioCareer 2010 Kuala Lumpur Convention Centre, Malaysia
Themed “Emerging Innovative Careers in Biotechnology”, the event was targeted at supporting Government initiatives to reduce unemployment and increase innovative careers in the
biotechnology industry. The 2-day career fair attracted almost 4500 visitors and a total of 40 exhibitors from various companies.
Fostering a Conducive Landscape for
November 1 - 3 BioMalaysia 2010 Conference & Exhibition Kuala Lumpur Convention Centre, Malaysia
This was the premier biotechnology event of the year for BiotechCorp to showcase latest research findings, state-of-the-art technology and new product launches. It also served as a platform for experts to engage in an exchange of knowledge, experiences and opinions in the development of the biotechnology industries. The event attracted over 7,400 participants from 17 countries.
November 13 - 14 BioCareer 2010 Kuala Lumpur Convention Centre, Malaysia
Themed “Emerging Innovative Careers in Biotechnology”, the event was targeted at supporting Government initiatives to reduce unemployment and increase innovative careers in the
biotechnology industry. The 2-day career fair attracted almost 4500 visitors and a total of 40 exhibitors from various companies.
Fostering a Conducive Landscape for Biotechnology Evolution
Legal & Regulatory
As the Malaysian biotechnology industry continues to be developed, the importance of having a robust and relevant legal and regulatory framework is imperative.
As the Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp) champions industry growth via the National Biotechnology Policy (NBP), the legal and regulatory function exists to ensure checks and balances are in place and the creation of an optimum regulatory environment that encourages further growth for the industry consistent with Thrust 7 of the NBP which emphasises the importance of establishing a solid and supportive regulatory framework for the development of biotechnology.
Focus Areas:
1. The establishment of a supportive regulatory framework and environment that takes into consideration the developmental aspirations of the nation and encourages innovation whilst ensuring public safety.
2. Contributing towards the balanced creation of safeguards to regulate access to local genetic resources, seeking not to hamper genuine initiatives and cooperation between the access provider and access seeker.
3. Contributing towards the development of a strong regulatory framework for intellectual property rights (IPR).
4. Encouraging the creation and filing of biotech-related patents with a view to commercialise.
5. The promotion and support initiatives for the attainment of international accreditation and compliance with international standards.
6. Contributing towards the establishment of a strong and enabling regulatory framework for the enhancement of efficacy in relation to product registration.
Key Results:
BioSafety Framework
Issue / Activity Result
Regulations under the Biosafety Framework provides certainty to the biotechnology industry that a specific process to handle the release, importation, exportation and contained use of living modified organisms (LMOs) has been put in place. BiotechCorp played a role in the promulgation of the law and actively
participated in the consultation exercise.
t 5IF#JP4BGFUZ"DUDBNFJOUPGPSDFPO%FDFNCFS 2007, while the Biosafety Regulations 2010 came into operation on November 1, 2010.
t 5IF$IJFG0QFSBUJOH0GGJDFSPG#JPUFDI$PSQXBTBQQPJOUFECZ
BioSafety Framework
Issue / Activity Result
t #JPUFDI$PSQIBTDPNNFODFEDPPQFSBUJPOXJUIUIF.JOJTUSZPG /BUVSBM3FTPVSDFTBOE&OWJSPONFOU .0/3&PODBQBDJUZ CVJMEJOHJOJUJBUJWFTUPGBDJMJUBUFBXBSFOFTTPGUIF"DUBOE SFHVMBUJPOTBNPOHJOEVTUSZQMBZFST
"DDFTT#FOFGJU 4IBSJOH "#4
)BWJOHBO"#4MBXXJMMFOTVSFUIBU.BMBZTJBJTBCMFUPDPNCBU CJPQJSBDZCFTJEFTQSPWJEJOHBOFGGFDUJWFNFBOTGPSUIFDPVOUSZUP DBQJUBMJTFVQPOJUTSJDIBOEEJWFSTFHFOFUJDSFTPVSDFTJOMJOFXJUI UIFDPVOUSZTPCKFDUJWFTUPQSPNPUFCJPUFDIOPMPHZEFWFMPQNFOU BTBOFOHJOFGPSHSPXUI
t 5IFSFBSFOPEPNFTUJD"#4MBXTUPEBUFCVUHJWFOJUT JNQPSUBODFUP.BMBZTJBBOE.BMBZTJBTNFNCFSTIJQJOUIF
$POGFSFODFPGUIF1BSUJFTUPUIF$POWFOUJPOPO#JPMPHJDBM
%JWFSTJUZ $#%JUJTBOUJDJQBUFEUIBUBGPSNBMEPNFTUJD"#4 GSBNFXPSLJTJOUIFQJQFMJOFBTUIF$POGFSFODFPGUIF1BSUJFTUP UIF$#%BUJUTUFOUINFFUJOHPO0DUPCFSJO/BHPZB +BQBOBEPQUFEUIF‘Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation to the Convention on Biological Diversity’.5IJTJTBOJOUFSOBUJPOBMBHSFFNFOUXIJDIJTBJNFEBU TIBSJOHUIFCFOFGJUTGSPNUIFVUJMJTBUJPOPGHFOFUJDSFTPVSDFTJO BGBJSBOEFRVJUBCMFBOEJUJTFYQFDUFEUIBUUIJT"HSFFNFOUXJMM BDDFMFSBUFQSPHSFTTJOUIFEFWFMPQNFOUPGUIFEPNFTUJD"#4 MBX5IF/BHPZB1SPUPDPMXJMMCFPQFOGPSTJHOBUVSFCZ1BSUJFTUP UIF$POWFOUJPOGSPN'FCSVBSZVOUJM'FCSVBSZ
*OUFMMFDUVBM1SPQFSUZ *1
#JPUFDI$PSQDPOUJOVFTUPXPSLUPXBSETDSFBUJOHBDPOEVDJWF MBOETDBQFGPSJOUFMMFDUVBMQSPQFSUZ
t 5IF*1SFHJTUSBUJPOUJNFMJOFTJO.BMBZTJBBSFFYQFDUFEUP
DPOTJEFSBCMZJNQSPWF%VSJOHUIFMBVODIPGUIF/BUJPOBM*1%BZPO
"QSJMUIF%FQVUZ1SJNF.JOJTUFSBOOPVODFEUIBUUIF
*OUFMMFDUVBM1SPQFSUZ$PSQPSBUJPOPG.BMBZTJB .Z*10JTOPX QVUUJOHBOFXUBSHFUPGNPOUITJOBOENPOUITJO GPSQBUFOUSFHJTUSBUJPO5PBTTJTU.Z*10JONFFUJOHUIJT DIBMMFOHF#JPUFDI$PSQJTGVOEJOHDPOUSBDUQBUFOUFYBNJOFST t #BTFEPOEFMJWFSBCMFTVOEFSUIFUI.BMBZTJB1MBO
#JPUFDI$PSQXBTBCMFUPQSPEVDFBUPUBMPGDFSUJGJFE QSPGFTTJPOBM*1NBOBHFSTGSPNVOEFSUIF .BMBZTJBO*OTUJUVUFPG.BOBHFNFOU$FSUJGJFE1SPGFTTJPOBM*1 .BOBHFS1SPHSBNNF5IFEJTUSJCVUJPOPGUIFQBSUJDJQBOUTGSPN UIJTQSPHSBNNFJTJMMVTUSBUFEJOUIFUBCMFCFMPX
Issue / Activity Result
*OUFMMFDUVBM1SPQFSUZ *1
1IBSNB3FHVMBUJPOT
t 6OEFSUIF1BUFOU$PPQFSBUJPO5SFBUZ 1$5.BMBZTJBXBTSBOLFE UIJOBUUIFHMPCBMMFWFMJOUIFOVNCFSPGBQQMJDBUJPOT GJMFE.BMBZTJBBDDFEFEUPUIF1$5JOBOETJODFUIFOUIF OVNCFSPGBQQMJDBUJPOTIBWFJODSFBTFECZ
1IBSNBDFVUJDBMTBSFSFHVMBUFECZUIF/BUJPOBM1IBSNBDFVUJDBM
$POUSPM#VSFBV /1$#PGUIF.JOJTUSZPG)FBMUIVOEFSUIF$POUSPM PG%SVHTBOE$PTNFUJDT3FHVMBUJPOTXIJDIFNQPXFSTUIF /1$#UPJNQMFNFOUUIFSFHJTUSBUJPOPG4DIFEVMFEQPJTPOT /POTDIFEVMFEQPJTPOT5SBEJUJPOBMNFEJDJOFTBOE$PTNFUJDT"
5FDIOJDBM8PSLJOH(SPVQ 58(GPSCJPUFDIQSPEVDUTXBT FTUBCMJTIFEUPQSFQBSFSFMFWBOUHVJEFMJOFTGPSCJPTJNJMBSQSPEVDUT BOEUIF58(TVDDFTTGVMMZDBNFVQXJUIUIF(VJEBODF%PDVNFOU BOE(VJEFMJOFTGPS3FHJTUSBUJPOPG#JPTJNJMBSTJO.BMBZTJBXIJDI XBTUIFOQVCMJTIFEPO"VHVTU
t *O#JPUFDI$PSQDPPSHBOJTFEXJUIUIF/1$#BXPSLTIPQ BU"4&"/MFWFMFOUJUMFEA"4&"/8PSLTIPQPO.FEJDBM%JDUJPOBSZ GPS3FHVMBUPSZ"DUJWJUJFT .FE%3"5SBJOJOH1SPHSBNBOEB A8PSLTIPQPO1SFQBSBUJPOPG1SPEVDU%PTTJFS4VCNJTTJPOGPS
#JPTJNJMBSThJO,VBMB-VNQVS
t "TBNFNCFSPG"4&"/.BMBZTJBDPOUJOVFTUPQMBZBOBDUJWFSPMF JOIBSNPOJTBUJPOFGGPSUTUISPVHIUIF"4&"/$POTVMUBUJWF
$PNNJUUFFGPS4UBOEBSETBOE2VBMJUZT "$$421IBSNBDFVUJDBM 1SPEVDU8PSLJOH(SPVQ 118(UIF5SBEJUJPOBM.FEJDJOFTBOE )FBMUI4VQQMFNFOUT1SPEVDU8PSLJOH(SPVQ 5.)418(BT XFMMBTUIF.FEJDBM%FWJDFT1SPEVDU8PSLJOH(SPVQ .%18( t #JPUFDI$PSQIBTBMTPQSPEVDFEBA3FHVMBUPSZ(VJEFCPPLPO
%PJOH#VTJOFTTJO64"BOE&VSPQF
Category No of Participants
Total 135
#JP/FYVT
3FTFBSDI*OTUJUVUJPOT 3*
*OTUJUVUFTPG)JHIFS
-FBSOJOH *)-T
(PWFSONFOU
BioSafety Framework
Issue / Activity Result
t #JPUFDI$PSQIBTDPNNFODFEDPPQFSBUJPOXJUIUIF.JOJTUSZPG /BUVSBM3FTPVSDFTBOE&OWJSPONFOU .0/3&PODBQBDJUZ CVJMEJOHJOJUJBUJWFTUPGBDJMJUBUFBXBSFOFTTPGUIF"DUBOE SFHVMBUJPOTBNPOHJOEVTUSZQMBZFST
"DDFTT#FOFGJU 4IBSJOH "#4
)BWJOHBO"#4MBXXJMMFOTVSFUIBU.BMBZTJBJTBCMFUPDPNCBU CJPQJSBDZCFTJEFTQSPWJEJOHBOFGGFDUJWFNFBOTGPSUIFDPVOUSZUP DBQJUBMJTFVQPOJUTSJDIBOEEJWFSTFHFOFUJDSFTPVSDFTJOMJOFXJUI UIFDPVOUSZTPCKFDUJWFTUPQSPNPUFCJPUFDIOPMPHZEFWFMPQNFOU BTBOFOHJOFGPSHSPXUI
t 5IFSFBSFOPEPNFTUJD"#4MBXTUPEBUFCVUHJWFOJUT JNQPSUBODFUP.BMBZTJBBOE.BMBZTJBTNFNCFSTIJQJOUIF
$POGFSFODFPGUIF1BSUJFTUPUIF$POWFOUJPOPO#JPMPHJDBM
%JWFSTJUZ $#%JUJTBOUJDJQBUFEUIBUBGPSNBMEPNFTUJD"#4 GSBNFXPSLJTJOUIFQJQFMJOFBTUIF$POGFSFODFPGUIF1BSUJFTUP UIF$#%BUJUTUFOUINFFUJOHPO0DUPCFSJO/BHPZB +BQBOBEPQUFEUIF‘Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation to the Convention on Biological Diversity’.5IJTJTBOJOUFSOBUJPOBMBHSFFNFOUXIJDIJTBJNFEBU TIBSJOHUIFCFOFGJUTGSPNUIFVUJMJTBUJPOPGHFOFUJDSFTPVSDFTJO BGBJSBOEFRVJUBCMFBOEJUJTFYQFDUFEUIBUUIJT"HSFFNFOUXJMM BDDFMFSBUFQSPHSFTTJOUIFEFWFMPQNFOUPGUIFEPNFTUJD"#4 MBX5IF/BHPZB1SPUPDPMXJMMCFPQFOGPSTJHOBUVSFCZ1BSUJFTUP UIF$POWFOUJPOGSPN'FCSVBSZVOUJM'FCSVBSZ
*OUFMMFDUVBM1SPQFSUZ *1
#JPUFDI$PSQDPOUJOVFTUPXPSLUPXBSETDSFBUJOHBDPOEVDJWF MBOETDBQFGPSJOUFMMFDUVBMQSPQFSUZ
t 5IF*1SFHJTUSBUJPOUJNFMJOFTJO.BMBZTJBBSFFYQFDUFEUP
DPOTJEFSBCMZJNQSPWF%VSJOHUIFMBVODIPGUIF/BUJPOBM*1%BZPO
"QSJMUIF%FQVUZ1SJNF.JOJTUFSBOOPVODFEUIBUUIF
*OUFMMFDUVBM1SPQFSUZ$PSQPSBUJPOPG.BMBZTJB .Z*10JTOPX QVUUJOHBOFXUBSHFUPGNPOUITJOBOENPOUITJO GPSQBUFOUSFHJTUSBUJPO5PBTTJTU.Z*10JONFFUJOHUIJT DIBMMFOHF#JPUFDI$PSQJTGVOEJOHDPOUSBDUQBUFOUFYBNJOFST t #BTFEPOEFMJWFSBCMFTVOEFSUIFUI.BMBZTJB1MBO
#JPUFDI$PSQXBTBCMFUPQSPEVDFBUPUBMPGDFSUJGJFE QSPGFTTJPOBM*1NBOBHFSTGSPNVOEFSUIF .BMBZTJBO*OTUJUVUFPG.BOBHFNFOU$FSUJGJFE1SPGFTTJPOBM*1 .BOBHFS1SPHSBNNF5IFEJTUSJCVUJPOPGUIFQBSUJDJQBOUTGSPN UIJTQSPHSBNNFJTJMMVTUSBUFEJOUIFUBCMFCFMPX
Issue / Activity Result
*OUFMMFDUVBM1SPQFSUZ *1
1IBSNB3FHVMBUJPOT
t 6OEFSUIF1BUFOU$PPQFSBUJPO5SFBUZ 1$5.BMBZTJBXBTSBOLFE UIJOBUUIFHMPCBMMFWFMJOUIFOVNCFSPGBQQMJDBUJPOT GJMFE.BMBZTJBBDDFEFEUPUIF1$5JOBOETJODFUIFOUIF OVNCFSPGBQQMJDBUJPOTIBWFJODSFBTFECZ
1IBSNBDFVUJDBMTBSFSFHVMBUFECZUIF/BUJPOBM1IBSNBDFVUJDBM
$POUSPM#VSFBV /1$#PGUIF.JOJTUSZPG)FBMUIVOEFSUIF$POUSPM PG%SVHTBOE$PTNFUJDT3FHVMBUJPOTXIJDIFNQPXFSTUIF /1$#UPJNQMFNFOUUIFSFHJTUSBUJPOPG4DIFEVMFEQPJTPOT /POTDIFEVMFEQPJTPOT5SBEJUJPOBMNFEJDJOFTBOE$PTNFUJDT"
5FDIOJDBM8PSLJOH(SPVQ 58(GPSCJPUFDIQSPEVDUTXBT FTUBCMJTIFEUPQSFQBSFSFMFWBOUHVJEFMJOFTGPSCJPTJNJMBSQSPEVDUT BOEUIF58(TVDDFTTGVMMZDBNFVQXJUIUIF(VJEBODF%PDVNFOU BOE(VJEFMJOFTGPS3FHJTUSBUJPOPG#JPTJNJMBSTJO.BMBZTJBXIJDI XBTUIFOQVCMJTIFEPO"VHVTU
t *O#JPUFDI$PSQDPPSHBOJTFEXJUIUIF/1$#BXPSLTIPQ BU"4&"/MFWFMFOUJUMFEA"4&"/8PSLTIPQPO.FEJDBM%JDUJPOBSZ GPS3FHVMBUPSZ"DUJWJUJFT .FE%3"5SBJOJOH1SPHSBNBOEB A8PSLTIPQPO1SFQBSBUJPOPG1SPEVDU%PTTJFS4VCNJTTJPOGPS
#JPTJNJMBSThJO,VBMB-VNQVS
t "TBNFNCFSPG"4&"/.BMBZTJBDPOUJOVFTUPQMBZBOBDUJWFSPMF JOIBSNPOJTBUJPOFGGPSUTUISPVHIUIF"4&"/$POTVMUBUJWF
$PNNJUUFFGPS4UBOEBSETBOE2VBMJUZT "$$421IBSNBDFVUJDBM 1SPEVDU8PSLJOH(SPVQ 118(UIF5SBEJUJPOBM.FEJDJOFTBOE )FBMUI4VQQMFNFOUT1SPEVDU8PSLJOH(SPVQ 5.)418(BT XFMMBTUIF.FEJDBM%FWJDFT1SPEVDU8PSLJOH(SPVQ .%18(
t #JPUFDI$PSQIBTBMTPQSPEVDFEBA3FHVMBUPSZ(VJEFCPPLPO
%PJOH#VTJOFTTJO64"BOE&VSPQF
Category No of Participants
Total 135
#JP/FYVT
3FTFBSDI*OTUJUVUJPOT 3*
*OTUJUVUFTPG)JHIFS
-FBSOJOH *)-T
(PWFSONFOU
Issue / Activity Result International
Accreditation - Good Laboratory Practices (GLP)
International
Accreditation - Good Clinical Practices (GCP)
The GLP Compliance Programme to certify adherence of test facilities to the Organisation for Economic Co-operation and Development (OECD) Principles of GLP and Compliance Monitoring have been initiated by the Malaysian Compliance Monitoring Authorities (see note below). BiotechCorp is currently working with these agencies in the certification of test facilities through the provision of funding for numerous capacity building initiatives. These includes the identification of potential test facilities for GLP compliance.
t *O(-1JOTQFDUJPOXFSFDPOEVDUFEPOOJOFDPNNJUUFEUFTU facilities in which three are found to be ready for testing in compliance to the OECD GLP requirements.
Note:
Malaysia was made a provisional adherent to the Organisation for Economic Co-operation and Development (OECD) Mutual
"DDFQUBODFPG%BUB ."%TZTUFNJO5IFZFBSTBX UIFDPOUJOVFEJNQMFNFOUBUJPOPGUIF0&$%(-1GSBNFXPSLXIJDI is applicable to non-clinical health and environment safety studies.
The Government had designated the National Pharmaceutical Control Bureau (NPCB) and Department of Standards Malaysia (Standards Malaysia) as the Malaysian Compliance Monitoring Authorities (CMAs). Malaysia intends to achieve full adherent TUBUVTUPUIF0&$%."%TZTUFNCZ
The Ministry of Health continues to ensure that each clinical trial proposal goes through a rigorous review and the trial itself is strictly monitored and regularly audited. The Clinical Research and Compliance Section of NPCB plays an important role in issuing the Clinical Trial Import License (CTIL) and ensuring compliance with GCP. The obvious benefit of GCP is acknowledged by NPCB as Malaysia becomes a more active participant in international drug research.
t *OTFWFO($1*OWFTUJHBUPSUSBJOJOHQSPHSBNNFTXFSF held in collaboration with the Clinical Research Centre (CRC) and the Associates of Clinical Research Professionals Malaysia "$31.XIFSFCZPWFS($1JOWFTUJHBUPSTXFSFUSBJOFE
Issue / Activity Result International
Accreditation – Good Clinical Practices (GCP)
t 'PVSPUIFSXPSLTIPQTDPOEVDUFEJOJODMVEFUIFA8PSLTIPQ for Study Directors and Quality Assurance Personnel of GLP 4UVEJFTA+PJOU$3$#JPUFDI$PSQ$MJOJDBM3FTFBSDI (PWFSOBODF&UIJDT8PSLTIPQBA4ZNQPTJVNPO
1IBSNBDFVUJDBM4DJFODFUP#VTJOFTTBOEA(PPE-BCPSBUPSZ 1SBDUJDF (-18PSLTIPQGPS4UVEZ%JSFDUPSTBOE2VBMJUZ Assurance Personnel of GLP Studies’.
Training Regulators In addition to creating awareness among industry players and the HFOFSBMQVCMJD#JPUFDI$PSQBTTJTUFEJOUIFUSBJOJOHPGLFZ regulators to create awareness and enhance their own skills in various important areas.
t Collaboration with the Intellectual Property Corporation of Malaysia .Z*10UPQSPWJEF*1-BXUSBJOJOHGPSUIFKVEJDJBSZPGGJDFSTPGUIF Attorney General’s Chambers and enforcement officers from the .JOJTUSZPG%PNFTUJD5SBEF$PPQFSBUJWFTBOE$POTVNFSJTNUP support the establishment of the IP Courts in Malaysia.
t $PMMBCPSBUJPOXJUI.Z*10UPQSPWJEFUSBJOJOHUPBQQSPYJNBUFMZ QBUFOUFYBNJOFSTGSPN.Z*10POTQFDJBMJTFEUSBJOJOHXJUI BOFYQFSUGSPNUIF,PSFBO1BUFOU0GGJDF ,*10BOEBMTPBO FYQFSUGBNJMJBSXJUIUIFQSPDFEVSFTBUUIF6OJUFE4UBUFT1BUFOU BOE5SBEFNBSL0GGJDF 64150UPJODSFBTFLOPXMFEHFBOE FOIBODFQBUFOUFYBNJOBUJPOTLJMMT
t $PMMBCPSBUJPOXJUIUIF/BUJPOBM1IBSNBDFVUJDBM$POUSPM#VSFBV (NPCB) of the Ministry of Health and the Department of
Standards Malaysia (STANDARDS MALAYSIA) of the Ministry of 4DJFODF5FDIOPMPHZBOE*OOPWBUJPO .045*UPQSPWJEFUIF Organisation for Economic Cooperation and Development’s (OECD) Principles of Good Laboratory Practices (GLP) training for their respective GLP inspectors worldwide so as to ensure quality inspections and smooth completion of the OECD GLP framework for Malaysia.
t $PMMBCPSBUJPOXJUI/1$#UPQSPWJEFUSBJOJOHUPBLFZSFHVMBUPS at the International Regulatory Conference on Herbal Medicine .FFUJOHBOE8PSLTIPQBOEPO2$3FRVJSFNFOUTGPS
#JPTJNJMBST.BOVGBDUVSJOHJO,VBMB-VNQVSUPFOIBODF awareness and skills in the quality aspects of biosimilars and herbal medicine.
Issue / Activity Result International
Accreditation - Good Laboratory Practices (GLP)
International
Accreditation - Good Clinical Practices (GCP)
The GLP Compliance Programme to certify adherence of test facilities to the Organisation for Economic Co-operation and Development (OECD) Principles of GLP and Compliance Monitoring have been initiated by the Malaysian Compliance Monitoring Authorities (see note below). BiotechCorp is currently working with these agencies in the certification of test facilities through the provision of funding for numerous capacity building initiatives. These includes the identification of potential test facilities for GLP compliance.
t *O(-1JOTQFDUJPOXFSFDPOEVDUFEPOOJOFDPNNJUUFEUFTU facilities in which three are found to be ready for testing in compliance to the OECD GLP requirements.
Note:
Malaysia was made a provisional adherent to the Organisation for Economic Co-operation and Development (OECD) Mutual
"DDFQUBODFPG%BUB ."%TZTUFNJO5IFZFBSTBX UIFDPOUJOVFEJNQMFNFOUBUJPOPGUIF0&$%(-1GSBNFXPSLXIJDI is applicable to non-clinical health and environment safety studies.
The Government had designated the National Pharmaceutical Control Bureau (NPCB) and Department of Standards Malaysia (Standards Malaysia) as the Malaysian Compliance Monitoring Authorities (CMAs). Malaysia intends to achieve full adherent TUBUVTUPUIF0&$%."%TZTUFNCZ
The Ministry of Health continues to ensure that each clinical trial proposal goes through a rigorous review and the trial itself is strictly monitored and regularly audited. The Clinical Research and Compliance Section of NPCB plays an important role in issuing the Clinical Trial Import License (CTIL) and ensuring compliance with GCP. The obvious benefit of GCP is acknowledged by NPCB as Malaysia becomes a more active participant in international drug research.
t *OTFWFO($1*OWFTUJHBUPSUSBJOJOHQSPHSBNNFTXFSF held in collaboration with the Clinical Research Centre (CRC) and the Associates of Clinical Research Professionals Malaysia "$31.XIFSFCZPWFS($1JOWFTUJHBUPSTXFSFUSBJOFE
Issue / Activity Result International
Accreditation – Good Clinical Practices (GCP)
t 'PVSPUIFSXPSLTIPQTDPOEVDUFEJOJODMVEFUIFA8PSLTIPQ for Study Directors and Quality Assurance Personnel of GLP 4UVEJFTA+PJOU$3$#JPUFDI$PSQ$MJOJDBM3FTFBSDI (PWFSOBODF&UIJDT8PSLTIPQBA4ZNQPTJVNPO
1IBSNBDFVUJDBM4DJFODFUP#VTJOFTTBOEA(PPE-BCPSBUPSZ 1SBDUJDF (-18PSLTIPQGPS4UVEZ%JSFDUPSTBOE2VBMJUZ Assurance Personnel of GLP Studies’.
Training Regulators In addition to creating awareness among industry players and the HFOFSBMQVCMJD#JPUFDI$PSQBTTJTUFEJOUIFUSBJOJOHPGLFZ regulators to create awareness and enhance their own skills in various important areas.
t Collaboration with the Intellectual Property Corporation of Malaysia .Z*10UPQSPWJEF*1-BXUSBJOJOHGPSUIFKVEJDJBSZPGGJDFSTPGUIF Attorney General’s Chambers and enforcement officers from the .JOJTUSZPG%PNFTUJD5SBEF$PPQFSBUJWFTBOE$POTVNFSJTNUP support the establishment of the IP Courts in Malaysia.
t $PMMBCPSBUJPOXJUI.Z*10UPQSPWJEFUSBJOJOHUPBQQSPYJNBUFMZ QBUFOUFYBNJOFSTGSPN.Z*10POTQFDJBMJTFEUSBJOJOHXJUI BOFYQFSUGSPNUIF,PSFBO1BUFOU0GGJDF ,*10BOEBMTPBO FYQFSUGBNJMJBSXJUIUIFQSPDFEVSFTBUUIF6OJUFE4UBUFT1BUFOU BOE5SBEFNBSL0GGJDF 64150UPJODSFBTFLOPXMFEHFBOE FOIBODFQBUFOUFYBNJOBUJPOTLJMMT
t $PMMBCPSBUJPOXJUIUIF/BUJPOBM1IBSNBDFVUJDBM$POUSPM#VSFBV (NPCB) of the Ministry of Health and the Department of
Standards Malaysia (STANDARDS MALAYSIA) of the Ministry of 4DJFODF5FDIOPMPHZBOE*OOPWBUJPO .045*UPQSPWJEFUIF Organisation for Economic Cooperation and Development’s (OECD) Principles of Good Laboratory Practices (GLP) training for their respective GLP inspectors worldwide so as to ensure quality inspections and smooth completion of the OECD GLP framework for Malaysia.
t $PMMBCPSBUJPOXJUI/1$#UPQSPWJEFUSBJOJOHUPBLFZSFHVMBUPS at the International Regulatory Conference on Herbal Medicine .FFUJOHBOE8PSLTIPQBOEPO2$3FRVJSFNFOUTGPS
#JPTJNJMBST.BOVGBDUVSJOHJO,VBMB-VNQVSUPFOIBODF awareness and skills in the quality aspects of biosimilars and herbal medicine.
Next Steps for Legal and Regulatory:
t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
t 0OUIF*1GSPOUUIFSFJTOFFEUPJODSFBTFBXBSFOFTTPOTUSBUFHJD*1NBOBHFNFOUBOEGPDVTPO BSFBTTVDIBTTFDVSJUJTBUJPOBOEDPMMBUFSBMJTBUJPOPG*1
t #JPUFDI$PSQIPQFTUPQBSUJDJQBUFBOEDPOUSJCVUFJOUIFEFWFMPQNFOUPGQIBSNBDFVUJDBMSFHVMBUJPOT BOE DPOUJOVF DPOTUSVDUJWF FOHBHFNFOU XJUI SFHVMBUPSZ TUBLFIPMEFST UP QSPWJEF BO BWFOVF GPS EJTDPVSTFBOEBMJHONFOUUPXBSETOBUJPOBMQPMJDJFT
t *OUFSNTPGJOUFSOBUJPOBMBDDSFEJUBUJPOXFIPQFUPTVQQPSU.BMBZTJBO$."T/1$#BOE4UBOEBSET .BMBZTJB JO BDIJFWJOH GVMM BEIFSFODF UP UIF 0&$% (-1 ."% TZTUFN CZ BOE BTTJTU JO UIF JEFOUJGJDBUJPOPGGBDJMJUJFTGPS(-1BDDSFEJUBUJPOJOUFSNTPGDBQBDJUZCVJMEJOHBOEUSBJOJOH
t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
t 8FMPPLGPSXBSEUPDPMMBCPSBUJPOTXJUI.JOJTUSZPG/BUVSBM3FTPVSDFTBOE&OWJSPONFOU .0/3&
BOE UIF .JOJTUSZ PG 4DJFODF 5FDIOPMPHZ BOE *OOPWBUJPO .045* UP DPOEVDU XPSLTIPQT PO CJPTBGFUZBOE"#4CFTJEFTQSPWJEJOHFYQPTVSFGPSLFZSFHVMBUPSTJOUIFTFBSFBTBTUIFSFJTB DSVDJBMOFFEUPCVJMEDBQBDJUZJOUIJTSFTQFDU
Financial Infrastructure
7JBJUTGJOBODJBMJOGSBTUSVDUVSFGVODUJPO#JPUFDI$PSQEFWFMPQTNFDIBOJTNTPGGVOEJOHGBDJMJUBUFT DPMMBCPSBUJPOT BOE BUUSBDUT JOWFTUNFOUT GPS UIF CJPUFDIOPMPHZ JOEVTUSZ *U BMTP JNQMFNFOUT QSPHSBNNFTUPQSPNPUFQSJWBUFJOWFTUNFOUJOUIFCJPUFDIOPMPHZJOEVTUSZ
Focus Areas:
%FWFMPQBOEJNQMFNFOUBDPNQSFIFOTJWFNFDIBOJTNPGGVOEJOHGPDVTJOHPOQSJPSJUZBSFBTGSPN SFTFBSDIUPNBSLFU
"DDFMFSBUFJOEVTUSZHSPXUIUISPVHITUSBUFHJDQBSUOFSTIJQTXJUIUIFEPNFTUJDBOEHMPCBMQSJWBUF TFDUPSTJODMVEJOH(PWFSONFOUMJOLFEDPNQBOJFTBOETQFDJGJDQSPHSBNNFT
&OTVSFNFDIBOJTNTGPSGVOEJOHXJUIUIFWFOUVSFDBQJUBMJOEVTUSZUIFCBOLJOHTFDUPSBOEUIF QSJWBUFTFDUPS
*OWFTUNFOUTJO Issue / Activity Key Results:
Result
5IF.BMBZTJBOCJPUFDIOPMPHZJOEVTUSZHSFXGVSUIFSJOXJUI JOWFTUNFOUTDPOUJOVJOHUPDPNFJOGSPNCPUIQVCMJDBOEQSJWBUF GVOEJOHTPVSDFT
t 5IFUPUBMBQQSPWFEJOWFTUNFOUTCZ#JP/FYVTDPNQBOJFTBNPVOUFE UP3.CJMMJPOBTBU%FDFNCFSBOJODSFBTFPG DPNQBSFEUP3.CJMMJPOBTBU%FDFNCFS5IJTJTJOMJOF XJUIUIFJODSFBTFJOUIFOVNCFSPG#JP/FYVTDPNQBOJFTGSPN DPNQBOJFTBUUIFFOEPGUPDPNQBOJFTBUUIFFOEPG t *OFGGPSUTUPQSPNPUFQSJWBUFJOWFTUNFOUTJOUIFCJPUFDIOPMPHZ
JOEVTUSZ#JPUFDI$PSQDPOUJOVFEUPFOHBHFXJUIWBSJPVTMPDBMBOE GPSFJHOJOWFTUPSTBOEJOUSPEVDFEQPUFOUJBMCJPUFDIOPMPHZEFBMGMPXT XJUIJOUIFDPSFCJPUFDIOPMPHZBSFBTPGBHSJDVMUVSBMIFBMUIDBSFBOE JOEVTUSJBMUPJOWFTUPSTTVDIBTQSJWBUFWFOUVSFDBQJUBMTQSJWBUF FOUJUJFTDPSQPSBUJPOTBOEGJOBODJBMJOTUJUVUJPOT&GGPSUTXFSFBMTP GPDVTFEPOGBDJMJUBUJOHBOENBUDIJOHCJPUFDIOPMPHZDPNQBOJFT BOEQSPKFDUTMPPLJOHGPSGVOEJOHXJUIQSJWBUFJOWFTUPSTPSGVOEFST t *OUFSOBUJPOBMJOWFTUNFOUTDPOUJOVFEUPGMPXJOUP.BMBZTJBEVSJOH
UIFQFSJPEVOEFSSFWJFXJOEJDBUJOHTUSPOHJOUFSFTUJOUIF .BMBZTJBOCJPUFDIOPMPHZJOEVTUSZ5IFOVNCFSPG#JP/FYVT 4UBUVTDPNQBOJFTXJUIJOUFSOBUJPOBMJOUFSFTU CPUINJOPSJUZ JOUFSFTUBOEDPOUSPMMJOHJOUFSFTUJODSFBTFECZGSPNJO UPJO5IFTFJOUFSOBUJPOBMJOWFTUNFOUTXFSF NBJOMZGSPN"VTUSBMJB#FMHJVN)PMMBOE*OEJB+BQBO4JOHBQPSF 5BJXBO6OJUFE,JOHEPN6OJUFE4UBUFT(FSNBOZBOE$IJOB
"NPOHUIFTFBSFJOUFSOBUJPOBMDPNQBOJFTBUUIFFOEPG XIJMTUUIFOVNCFSJODSFBTFUPBUUIFFOEPGXJUI BUPUBMBQQSPWFEJOWFTUNFOUGPSUIFBEEJUJPOBMJOUFSOBUJPOBM DPNQBOJFTBNPVOUJOHUP3.NJMMJPO
'VOESBJTJOHGPS CJPUFDIOPMPHZ DPNQBOJFTUISPVHI UIFDBQJUBMNBSLFU
#JPUFDIOPMPHZDPNQBOJFTIBWFBMTPSBJTFEGVOETUISPVHIUIF DBQJUBMNBSLFU
t 5IF.BMBZTJBO(FOPNJDT3FTPVSDF#FSIBE .(3$B
#JP/FYVTTUBUVTDPNQBOZIFBEFEGPSBTUPDLNBSLFUMJTUJOHPO UIF"$&NBSLFUPG#VSTB.BMBZTJBPO0DUPCFS5IF MJTUJOHFYFSDJTFFOUBJMTUIFJTTVBODFPGOFXNJMMJPOTIBSFTJO UIFDPNQBOZBOEBOPGGFSGPSTBMFPGUXPNJMMJPOFYJTUJOHTIBSFT SBJTJOHBUPUBMPG3.NJMMJPO8JUIUIFMJTUJOHPG.(3$UIFSF BSFJOUPUBMGJWFMJTUFE#JP/FYVTDPNQBOJFTPOUIFMPDBMBTXFMM BTGPSFJHOFYDIBOHFT0UIFSMJTUFE#JP/FYVTDPNQBOJFTJODMVEF 4UFNMJGF#FSIBEBOE4VO[FO#JPUFDI#FSIBE #VSTB.BMBZTJB )PMJTUB$PMMUFDI "VTUSBMJBO4FDVSJUJFT&YDIBOHF "49BOE1VSF
$JSDMF "*.-POEPO4UPDL&YDIBOHF
Next Steps for Legal and Regulatory:
t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
t 0OUIF*1GSPOUUIFSFJTOFFEUPJODSFBTFBXBSFOFTTPOTUSBUFHJD*1NBOBHFNFOUBOEGPDVTPO BSFBTTVDIBTTFDVSJUJTBUJPOBOEDPMMBUFSBMJTBUJPOPG*1
t #JPUFDI$PSQIPQFTUPQBSUJDJQBUFBOEDPOUSJCVUFJOUIFEFWFMPQNFOUPGQIBSNBDFVUJDBMSFHVMBUJPOT BOE DPOUJOVF DPOTUSVDUJWF FOHBHFNFOU XJUI SFHVMBUPSZ TUBLFIPMEFST UP QSPWJEF BO BWFOVF GPS EJTDPVSTFBOEBMJHONFOUUPXBSETOBUJPOBMQPMJDJFT
t *OUFSNTPGJOUFSOBUJPOBMBDDSFEJUBUJPOXFIPQFUPTVQQPSU.BMBZTJBO$."T/1$#BOE4UBOEBSET .BMBZTJB JO BDIJFWJOH GVMM BEIFSFODF UP UIF 0&$% (-1 ."% TZTUFN CZ BOE BTTJTU JO UIF JEFOUJGJDBUJPOPGGBDJMJUJFTGPS(-1BDDSFEJUBUJPOJOUFSNTPGDBQBDJUZCVJMEJOHBOEUSBJOJOH
t *O LFFQJOH SFHVMBUPST VQ UP TQFFE XJUI LOPXMFEHF BOE UIF MBUFTU JO UIF JOEVTUSZ #JPUFDI$PSQ IPQFTUPDPMMBCPSBUFXJUIUIF/1$#UPQSPWJEFUSBJOJOHGPSLFZSFHVMBUPSTJOUIFSFWJFXPGESVH EFWFMPQNFOU JO DMJOJDBM USJBMT JO UIF (-1 $PNQMJBODF 1SPHSBNNF BOE JO ESVH SFHVMBUPSZ BVUIPSJUJFT FGGPSUT UP IBSNPOJTF SFHVMBUJPOT BOE JNQSPWF UIF TBGFUZ FGGJDBDZ BOE RVBMJUZ PG NFEJDJOFT1BSUJDJQBUJPOJOUIFQSPQPTFEUSBJOJOHOPUPOMZFOIBODFTUIFDBQBDJUZBOEDPNQFUFODZ PG/1$#TQFSTPOOFMCVUBMTPPGGFSTBDIBODFGPS/1$#UPCVJMEUIFJSOFUXPSLXJUIPUIFSSFHVMBUPSZ BVUIPSJUJFTXPSMEXJEF
t 8FMPPLGPSXBSEUPDPMMBCPSBUJPOTXJUI.JOJTUSZPG/BUVSBM3FTPVSDFTBOE&OWJSPONFOU .0/3&
BOE UIF .JOJTUSZ PG 4DJFODF 5FDIOPMPHZ BOE *OOPWBUJPO .045* UP DPOEVDU XPSLTIPQT PO CJPTBGFUZBOE"#4CFTJEFTQSPWJEJOHFYQPTVSFGPSLFZSFHVMBUPSTJOUIFTFBSFBTBTUIFSFJTB DSVDJBMOFFEUPCVJMEDBQBDJUZJOUIJTSFTQFDU
Financial Infrastructure
7JBJUTGJOBODJBMJOGSBTUSVDUVSFGVODUJPO#JPUFDI$PSQEFWFMPQTNFDIBOJTNTPGGVOEJOHGBDJMJUBUFT DPMMBCPSBUJPOT BOE BUUSBDUT JOWFTUNFOUT GPS UIF CJPUFDIOPMPHZ JOEVTUSZ *U BMTP JNQMFNFOUT QSPHSBNNFTUPQSPNPUFQSJWBUFJOWFTUNFOUJOUIFCJPUFDIOPMPHZJOEVTUSZ
Focus Areas:
%FWFMPQBOEJNQMFNFOUBDPNQSFIFOTJWFNFDIBOJTNPGGVOEJOHGPDVTJOHPOQSJPSJUZBSFBTGSPN SFTFBSDIUPNBSLFU
"DDFMFSBUFJOEVTUSZHSPXUIUISPVHITUSBUFHJDQBSUOFSTIJQTXJUIUIFEPNFTUJDBOEHMPCBMQSJWBUF TFDUPSTJODMVEJOH(PWFSONFOUMJOLFEDPNQBOJFTBOETQFDJGJDQSPHSBNNFT
&OTVSFNFDIBOJTNTGPSGVOEJOHXJUIUIFWFOUVSFDBQJUBMJOEVTUSZUIFCBOLJOHTFDUPSBOEUIF
*OWFTUNFOUTJO Issue / Activity Key Results:
Result
5IF.BMBZTJBOCJPUFDIOPMPHZJOEVTUSZHSFXGVSUIFSJOXJUI JOWFTUNFOUTDPOUJOVJOHUPDPNFJOGSPNCPUIQVCMJDBOEQSJWBUF GVOEJOHTPVSDFT
t 5IFUPUBMBQQSPWFEJOWFTUNFOUTCZ#JP/FYVTDPNQBOJFTBNPVOUFE UP3.CJMMJPOBTBU%FDFNCFSBOJODSFBTFPG DPNQBSFEUP3.CJMMJPOBTBU%FDFNCFS5IJTJTJOMJOF XJUIUIFJODSFBTFJOUIFOVNCFSPG#JP/FYVTDPNQBOJFTGSPN DPNQBOJFTBUUIFFOEPGUPDPNQBOJFTBUUIFFOEPG t *OFGGPSUTUPQSPNPUFQSJWBUFJOWFTUNFOUTJOUIFCJPUFDIOPMPHZ
JOEVTUSZ#JPUFDI$PSQDPOUJOVFEUPFOHBHFXJUIWBSJPVTMPDBMBOE GPSFJHOJOWFTUPSTBOEJOUSPEVDFEQPUFOUJBMCJPUFDIOPMPHZEFBMGMPXT XJUIJOUIFDPSFCJPUFDIOPMPHZBSFBTPGBHSJDVMUVSBMIFBMUIDBSFBOE JOEVTUSJBMUPJOWFTUPSTTVDIBTQSJWBUFWFOUVSFDBQJUBMTQSJWBUF FOUJUJFTDPSQPSBUJPOTBOEGJOBODJBMJOTUJUVUJPOT&GGPSUTXFSFBMTP GPDVTFEPOGBDJMJUBUJOHBOENBUDIJOHCJPUFDIOPMPHZDPNQBOJFT BOEQSPKFDUTMPPLJOHGPSGVOEJOHXJUIQSJWBUFJOWFTUPSTPSGVOEFST t *OUFSOBUJPOBMJOWFTUNFOUTDPOUJOVFEUPGMPXJOUP.BMBZTJBEVSJOH
UIFQFSJPEVOEFSSFWJFXJOEJDBUJOHTUSPOHJOUFSFTUJOUIF .BMBZTJBOCJPUFDIOPMPHZJOEVTUSZ5IFOVNCFSPG#JP/FYVT 4UBUVTDPNQBOJFTXJUIJOUFSOBUJPOBMJOUFSFTU CPUINJOPSJUZ JOUFSFTUBOEDPOUSPMMJOHJOUFSFTUJODSFBTFECZGSPNJO UPJO5IFTFJOUFSOBUJPOBMJOWFTUNFOUTXFSF NBJOMZGSPN"VTUSBMJB#FMHJVN)PMMBOE*OEJB+BQBO4JOHBQPSF 5BJXBO6OJUFE,JOHEPN6OJUFE4UBUFT(FSNBOZBOE$IJOB
"NPOHUIFTFBSFJOUFSOBUJPOBMDPNQBOJFTBUUIFFOEPG XIJMTUUIFOVNCFSJODSFBTFUPBUUIFFOEPGXJUI BUPUBMBQQSPWFEJOWFTUNFOUGPSUIFBEEJUJPOBMJOUFSOBUJPOBM DPNQBOJFTBNPVOUJOHUP3.NJMMJPO
'VOESBJTJOHGPS CJPUFDIOPMPHZ DPNQBOJFTUISPVHI UIFDBQJUBMNBSLFU
#JPUFDIOPMPHZDPNQBOJFTIBWFBMTPSBJTFEGVOETUISPVHIUIF DBQJUBMNBSLFU
t 5IF.BMBZTJBO(FOPNJDT3FTPVSDF#FSIBE .(3$B
#JP/FYVTTUBUVTDPNQBOZIFBEFEGPSBTUPDLNBSLFUMJTUJOHPO UIF"$&NBSLFUPG#VSTB.BMBZTJBPO0DUPCFS5IF MJTUJOHFYFSDJTFFOUBJMTUIFJTTVBODFPGOFXNJMMJPOTIBSFTJO UIFDPNQBOZBOEBOPGGFSGPSTBMFPGUXPNJMMJPOFYJTUJOHTIBSFT SBJTJOHBUPUBMPG3.NJMMJPO8JUIUIFMJTUJOHPG.(3$UIFSF BSFJOUPUBMGJWFMJTUFE#JP/FYVTDPNQBOJFTPOUIFMPDBMBTXFMM BTGPSFJHOFYDIBOHFT0UIFSMJTUFE#JP/FYVTDPNQBOJFTJODMVEF 4UFNMJGF#FSIBEBOE4VO[FO#JPUFDI#FSIBE #VSTB.BMBZTJB )PMJTUB$PMMUFDI "VTUSBMJBO4FDVSJUJFT&YDIBOHF "49BOE1VSF
Establishment of funds to assist the industry
Issue / Activity Key Results:
Result
BiotechCorp provides assistance towards efforts to establish dedicated biotechnology funds.
t *O#JPUFDI$PSQBTTJTUFE*.#/7FOUVSF$P-UEBKPJOU WFOUVSFCFUXFFO"TJB1BDJGJD*OUFSOBUJPOBM.PMFDVMBS#JPMPHZ /FUXPSL "*.#/BOEUIF5TVOBNJHSPVQPG+BQBOUPFTUBCMJTI a dedicated biotechnology fund with an initial target fund size of 3.NJMMJPO*.#/7FOUVSFXBTBTTJTUFEXJUINFFUJOHTXJUI potential investors and partners as well as its application to SFHJTUFSBTBA7FOUVSF$BQJUBM.BOBHFNFOU$PNQBOZXJUIUIF Securities Commission.
t *OBEEJUJPOUIFSFXFSFBMTPJORVJSJFTGSPNWFOUVSFDBQJUBMJTUT GSPNUIF644JOHBQPSFBOE(FSNBOZUPTFUVQCJPUFDIOPMPHZ funds focusing on medical device and biomass respectively.
Raising awareness on funding
opportunities and encouraging investment
BiotechCorp continued to create awareness and interest among the financial and investment community on the business and UFDIOJDBMBTQFDUTPGUIFCJPUFDIOPMPHZTFDUPSMPDBMMZBOEHMPCBMMZ with the intention for them to eventually consider investment within the industry.
t #JPUFDI$PSQPSHBOJTFEUIF#JP'VOEJOH$POGFSFODFUIF second to be held following the success of the conference in 5IJTZFBShTDPOGFSFODFXBTBQMBUGPSNUPGFBUVSFNPSF HMPCBMQFSTQFDUJWFTHJWFOUIFNBKPSJUZPGJOUFSOBUJPOBM
QSFTFOUFSTTQFBLFST*UBUUSBDUFEBUPUBMPGQBSUJDJQBOUT DPNJOHGSPNPSHBOJTBUJPOTTVDIBT(PWFSONFOUMJOLFEGVOEFST WFOUVSFDBQJUBMJTUT 7$TBOEQSJWBUFFRVJUJFTGJSNT 1&T GJOBODJBMJOTUJUVUJPOTDPSQPSBUJPOTBTXFMMBTDPSQPSBUFBEWJTFST BOEDPOTVMUBOUT#JP/FYVTDPNQBOJFTUIBUQBSUJDJQBUFEJOUIF conference benefited immensely as it provided them with overviews of the global biotechnology landscape and the three TVCTFDUPSTPGCJPUFDIJFBHSJDVMUVSFIFBMUIDBSFBOEJOEVTUSJBM BTXFMMBTUIFFYQFDUBUJPOPGJOWFTUPSTBOEGVOEFSTXIFO JOWFTUJOHJOUIFJSCVTJOFTT5IFDPOGFSFODFQSPWJEFEBOBWFOVF GPSUIFNUPOFUXPSLXJUIUIFJOWFTUPSTBOEGVOEFST
t "MTPJOB#JP'VOEJOH8PSLTIPQGPDVTJOHPOUIFWBMVBUJPO PGCJPUFDIOPMPHZBOEMJGFTDJFODFTDPNQBOJFTXBTPSHBOJTFE XJUIQBSUJDJQBOUTGSPN(PWFSONFOUMJOLFEGVOEFST7$TBOE1&T fnancial institutions as well as corporations.
BioEducation 4ZNQPTJVN Issue / Activity Key Results:
Result
5IF4ZNQPTJVNXBTIFMEUPEFWFMPQBXBSFOFTTBNPOHTUTDJFODF teachers and career counsellors about biotechnology fields and available career opportunities so they would be able to provide this information to students.
t "UPUBMPGQBSUJDJQBOUTXFSFJOWPMWFEJOUIF#JP&EVDBUJPO 4ZNQPTJVNIFMEPO.BSDIBU-F.FSJEJFO 4IFSBUPO*NQFSJBM,VBMB-VNQVS
Biotechnology Entrepreneurship 4QFDJBM5SBJOJOH #F451SPHSBNNF BOE(SBEVBUJPO
#F45JTQBSUPG#JPUFDI$PSQhTBQQSPBDIUPEFWFMPQBOEOVSUVSF TLJMMFEUBMFOUXJUIJOUIFJOEVTUSZJOBCJEUPFOTVSFBTVTUBJOBCMF QPPMPGIVNBODBQJUBMGPS.BMBZTJB
t 5IFHSBEVBUJPODFSFNPOZGPSUIPTFXIPXFOUUISPVHIUIF#F45 QSPHSBNNFXBTIFMEPO+VMZBU4IFSBUPO*NQFSJBM,VBMB -VNQVSUPDFMFCSBUFSFDPHOJTFBOEHJWFBQQSFDJBUJPOUPBMM trainees after having been enrolled in the three months DMBTTSPPNCBTFEUSBJOJOH
Next Steps for Financial Infrastructure Development:
t $POUJOVPVT FOHBHFNFOU JOEVTUSZ QMBZFST (PWFSONFOU BHFODJFT BOE JOWFTUPST UP QSPNPUF JOWFTUNFOUJOUIFCJPUFDIOPMPHZJOEVTUSZJO.BMBZTJBCZGBDJMJUBUJOHBOENBUDIJOHCJPUFDIOPMPHZ companies with potential investors.
t *ODSFBTJOH JOWFTUNFOUT EJSFDUMZ PS JOEJSFDUMZ UISPVHI EFWFMPQJOH BOE FYFDVUJOHJNQMFNFOUJOH funding mechanism such as engaging local and foreign parties in establishing biotechnology GVOETDPMMBCPSBUJPOXJUIMPDBMDPSQPSBUJPOTGPSJOWFTUNFOUJOCJPUFDIOPMPHZUISPVHIQSJWBUFQVCMJD QBSUOFSTIJQ NPEFMT BOE DPMMBCPSBUJPO XJUI PUIFS (PWFSONFOU NJOJTUSJFTBHFODJFT PO GVOEJOH related matters.
Human Capital Development
"OJOEVTUSZJTPOMZBTHPPEBTUIFQFPQMFXIPBSFJOWPMWFEJOJU*OUIJTDPOUFYUUIFRVBMJUZPG IVNBO DBQJUBM JT BO JNQPSUBOU BTQFDU JO VOEFSUBLJOH BOZ JOEVTUSZ EFWFMPQNFOU JOJUJBUJWF
#JPUFDI$PSQIBSCPVSTUIFBTQJSBUJPOPGDSFBUJOHXPSMEDMBTTQSPGFTTJPOBMTJOUIFJOEVTUSZUPBDUBT DBUBMZTUTUIBUXJMMTQVSHSFBUFSNBHOJUVEFTPGHSPXUIGPSUIFJOEVTUSZ*OUIJTSFHBSEUIFBVEJFODF GPS IVNBO DBQJUBM EFWFMPQNFOU JOJUJBUJWF SBOHF GSPN TDIPPM HPJOH DIJMESFO XIP BSF QPUFOUJBM JOEVTUSZQMBZFSTJOUIFGVUVSFSJHIUVQUPQSPGFTTJPOBMTBOEDPSQPSBUFDBQUBJOT
Focus Areas:
%FWFMPQTLJMMFELOPXMFEHFBCMFBOEDPNQFUFOUIVNBODBQJUBMUPFOTVSFBEFRVBUFTVQQMZPG human capital for the biotechnology ecosystem.
%FWFMPQDBQBCJMJUJFTBDSPTTUIFCJPUFDIOPMPHZWBMVFDIBJOGSPNSFTFBSDIUPDPNNFSDJBMJTBUJPO CVTJOFTTEFWFMPQNFOUQSPEVDUEFWFMPQNFOUQSPEVDUJPOBOENBSLFUJOH
Establishment of funds to assist the industry
Issue / Activity Key Results:
Result
BiotechCorp provides assistance towards efforts to establish dedicated biotechnology funds.
t *O#JPUFDI$PSQBTTJTUFE*.#/7FOUVSF$P-UEBKPJOU WFOUVSFCFUXFFO"TJB1BDJGJD*OUFSOBUJPOBM.PMFDVMBS#JPMPHZ /FUXPSL "*.#/BOEUIF5TVOBNJHSPVQPG+BQBOUPFTUBCMJTI a dedicated biotechnology fund with an initial target fund size of 3.NJMMJPO*.#/7FOUVSFXBTBTTJTUFEXJUINFFUJOHTXJUI potential investors and partners as well as its application to SFHJTUFSBTBA7FOUVSF$BQJUBM.BOBHFNFOU$PNQBOZXJUIUIF Securities Commission.
t *OBEEJUJPOUIFSFXFSFBMTPJORVJSJFTGSPNWFOUVSFDBQJUBMJTUT GSPNUIF644JOHBQPSFBOE(FSNBOZUPTFUVQCJPUFDIOPMPHZ funds focusing on medical device and biomass respectively.
Raising awareness on funding
opportunities and encouraging investment
BiotechCorp continued to create awareness and interest among the financial and investment community on the business and UFDIOJDBMBTQFDUTPGUIFCJPUFDIOPMPHZTFDUPSMPDBMMZBOEHMPCBMMZ with the intention for them to eventually consider investment within the industry.
t #JPUFDI$PSQPSHBOJTFEUIF#JP'VOEJOH$POGFSFODFUIF second to be held following the success of the conference in 5IJTZFBShTDPOGFSFODFXBTBQMBUGPSNUPGFBUVSFNPSF HMPCBMQFSTQFDUJWFTHJWFOUIFNBKPSJUZPGJOUFSOBUJPOBM
QSFTFOUFSTTQFBLFST*UBUUSBDUFEBUPUBMPGQBSUJDJQBOUT DPNJOHGSPNPSHBOJTBUJPOTTVDIBT(PWFSONFOUMJOLFEGVOEFST WFOUVSFDBQJUBMJTUT 7$TBOEQSJWBUFFRVJUJFTGJSNT 1&T GJOBODJBMJOTUJUVUJPOTDPSQPSBUJPOTBTXFMMBTDPSQPSBUFBEWJTFST BOEDPOTVMUBOUT#JP/FYVTDPNQBOJFTUIBUQBSUJDJQBUFEJOUIF conference benefited immensely as it provided them with overviews of the global biotechnology landscape and the three TVCTFDUPSTPGCJPUFDIJFBHSJDVMUVSFIFBMUIDBSFBOEJOEVTUSJBM BTXFMMBTUIFFYQFDUBUJPOPGJOWFTUPSTBOEGVOEFSTXIFO JOWFTUJOHJOUIFJSCVTJOFTT5IFDPOGFSFODFQSPWJEFEBOBWFOVF GPSUIFNUPOFUXPSLXJUIUIFJOWFTUPSTBOEGVOEFST
t "MTPJOB#JP'VOEJOH8PSLTIPQGPDVTJOHPOUIFWBMVBUJPO PGCJPUFDIOPMPHZBOEMJGFTDJFODFTDPNQBOJFTXBTPSHBOJTFE XJUIQBSUJDJQBOUTGSPN(PWFSONFOUMJOLFEGVOEFST7$TBOE1&T fnancial institutions as well as corporations.
BioEducation 4ZNQPTJVN Issue / Activity Key Results:
Result
5IF4ZNQPTJVNXBTIFMEUPEFWFMPQBXBSFOFTTBNPOHTUTDJFODF teachers and career counsellors about biotechnology fields and available career opportunities so they would be able to provide this information to students.
t "UPUBMPGQBSUJDJQBOUTXFSFJOWPMWFEJOUIF#JP&EVDBUJPO 4ZNQPTJVNIFMEPO.BSDIBU-F.FSJEJFO 4IFSBUPO*NQFSJBM,VBMB-VNQVS
Biotechnology Entrepreneurship 4QFDJBM5SBJOJOH #F451SPHSBNNF BOE(SBEVBUJPO
#F45JTQBSUPG#JPUFDI$PSQhTBQQSPBDIUPEFWFMPQBOEOVSUVSF TLJMMFEUBMFOUXJUIJOUIFJOEVTUSZJOBCJEUPFOTVSFBTVTUBJOBCMF QPPMPGIVNBODBQJUBMGPS.BMBZTJB
t 5IFHSBEVBUJPODFSFNPOZGPSUIPTFXIPXFOUUISPVHIUIF#F45 QSPHSBNNFXBTIFMEPO+VMZBU4IFSBUPO*NQFSJBM,VBMB -VNQVSUPDFMFCSBUFSFDPHOJTFBOEHJWFBQQSFDJBUJPOUPBMM trainees after having been enrolled in the three months Next Steps for Financial Infrastructure Development:
t $POUJOVPVT FOHBHFNFOU JOEVTUSZ QMBZFST (PWFSONFOU BHFODJFT BOE JOWFTUPST UP QSPNPUF JOWFTUNFOUJOUIFCJPUFDIOPMPHZJOEVTUSZJO.BMBZTJBCZGBDJMJUBUJOHBOENBUDIJOHCJPUFDIOPMPHZ companies with potential investors.
t *ODSFBTJOH JOWFTUNFOUT EJSFDUMZ PS JOEJSFDUMZ UISPVHI EFWFMPQJOH BOE FYFDVUJOHJNQMFNFOUJOH funding mechanism such as engaging local and foreign parties in establishing biotechnology GVOETDPMMBCPSBUJPOXJUIMPDBMDPSQPSBUJPOTGPSJOWFTUNFOUJOCJPUFDIOPMPHZUISPVHIQSJWBUFQVCMJD QBSUOFSTIJQ NPEFMT BOE DPMMBCPSBUJPO XJUI PUIFS (PWFSONFOU NJOJTUSJFTBHFODJFT PO GVOEJOH related matters.
Human Capital Development
"OJOEVTUSZJTPOMZBTHPPEBTUIFQFPQMFXIPBSFJOWPMWFEJOJU*OUIJTDPOUFYUUIFRVBMJUZPG IVNBO DBQJUBM JT BO JNQPSUBOU BTQFDU JO VOEFSUBLJOH BOZ JOEVTUSZ EFWFMPQNFOU JOJUJBUJWF
#JPUFDI$PSQIBSCPVSTUIFBTQJSBUJPOPGDSFBUJOHXPSMEDMBTTQSPGFTTJPOBMTJOUIFJOEVTUSZUPBDUBT DBUBMZTUTUIBUXJMMTQVSHSFBUFSNBHOJUVEFTPGHSPXUIGPSUIFJOEVTUSZ*OUIJTSFHBSEUIFBVEJFODF GPS IVNBO DBQJUBM EFWFMPQNFOU JOJUJBUJWF SBOHF GSPN TDIPPM HPJOH DIJMESFO XIP BSF QPUFOUJBM JOEVTUSZQMBZFSTJOUIFGVUVSFSJHIUVQUPQSPGFTTJPOBMTBOEDPSQPSBUFDBQUBJOT
Focus Areas:
%FWFMPQTLJMMFELOPXMFEHFBCMFBOEDPNQFUFOUIVNBODBQJUBMUPFOTVSFBEFRVBUFTVQQMZPG human capital for the biotechnology ecosystem.
%FWFMPQDBQBCJMJUJFTBDSPTTUIFCJPUFDIOPMPHZWBMVFDIBJOGSPNSFTFBSDIUPDPNNFSDJBMJTBUJPO CVTJOFTTEFWFMPQNFOUQSPEVDUEFWFMPQNFOUQSPEVDUJPOBOENBSLFUJOH